Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105)-Reference-Cited by-同舟云学术

Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105)

Published:2014-06-13 Issue:2 Volume:136 Page:452-461
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Toi Hirofumi¹²,Tsujie Masanori¹³,Haruta Yuro¹⁴,Fujita Kanako¹,Duzen Jill¹,Seon Ben K.¹

Affiliation:

1. Department of Immunology; Roswell Park Cancer Institute; Buffalo NY

2. Department of Surgery; Megumino Hospital; Eniwa Hokkaido Japan

3. Department of Surgery; Nara Hospital, Kinki University School of Medicine; Ikoma Nara Japan

4. Matsuonaika Hospital; Mihara Hiroshima Japan

Funder

Clinical Translational Research grant, from the Department of Defense Breast Cancer Research Program

Tracon Pharma, a Roswell Park Alliance Foundation grant

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference46 articles.

1. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis;Ebos;Nat Rev Clin Oncol,2011

2. Combining antiangiogenics to overcome resistance: rationale and clinical experience;Moreno Garcia;Clin Cancer Res,2012

3. Antiangiogenic therapy-evolving view based on clinical trial results;Jayson;Nat Rev Clin Oncol,2012

4. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin;Seon;Clin Cancer Res,1997

5. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies;Matsuno;Clin Cancer Res,1999

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target;Clinical and Translational Oncology;2022-02-15

2. SARS-CoV-2 Infection in Hereditary Hemorrhagic Telangiectasia Patients Suggests Less Clinical Impact Than in the General Population;Journal of Clinical Medicine;2021-04-27

3. Nanoparticle-Based Drug Delivery Systems for Enhanced Tumor-Targeting Treatment;Journal of Biomedical Nanotechnology;2019-01-01

4. Targeting Strategies for the Combination Treatment of Cancer Using Drug Delivery Systems;Pharmaceutics;2017-10-14

5. ALK1 signaling in development and disease: new paradigms;Cellular and Molecular Life Sciences;2017-09-04